
Pituitary Adenylate Cyclase-Activating Polypeptide: A Promising Neuroprotective Peptide in Stroke
Author(s) -
Yuanjian Fang,
Reng Ren,
Hui Shi,
Lei Huang,
Cameron Lenahan,
Qin Lü,
Lihui Tang,
Yi Huang,
Jiping Tang,
Jianmin Zhang,
Junyi Zhang
Publication year - 2020
Publication title -
aging and disease
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.808
H-Index - 54
ISSN - 2152-5250
DOI - 10.14336/ad.2020.0626
Subject(s) - neuroprotection , excitotoxicity , pituitary adenylate cyclase activating peptide , medicine , pharmacology , stroke (engine) , neuroscience , bioinformatics , receptor , neuropeptide , vasoactive intestinal peptide , biology , glutamate receptor , mechanical engineering , engineering
The search for viable, effective treatments for acute stroke continues to be a global priority due to the high mortality and morbidity. Current therapeutic treatments have limited effects, making the search for new treatments imperative. Pituitary adenylate cyclase-activating polypeptide (PACAP) is a well-established cytoprotective neuropeptide that participates in diverse neural physiological and pathological activities, such as neuronal proliferation, differentiation, and migration, as well as neuroprotection. It is considered a promising treatment in numerous neurological diseases. Thus, PACAP bears potential as a new therapeutic strategy for stroke treatment. Herein, we provide an overview pertaining to the current knowledge of PACAP, its receptors, and its potential neuroprotective role in the setting of stroke, as well as various mechanisms of neuroprotection involving ionic homeostasis, excitotoxicity, cell edema, oxidative stress, inflammation, and cell death, as well as the route of PACAP administration.